This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Qutenza(R) (capsaicin) 8% Patch For Treatment Of Post-Shingles Pain Now Available

SAN MATEO, Calif., April 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available. Clinical studies have shown that a single one-hour Qutenza application can provide three months relief from pain associated with postherpetic neuralgia (PHN), the nerve pain that can occur after shingles.

In November 2009, Qutenza was approved by the U.S. Food and Drug Administration (FDA) for the management of neuropathic pain associated with PHN. Qutenza, the first product from NeurogesX, is now available through selected specialty distributors and a specialty pharmacy -- a complete list of these distributors is available at www.Qutenza.com.

Qutenza is the first prescription-strength topical treatment for PHN to be approved by the FDA in more than 10 years. Qutenza harnesses the power of capsaicin in a dermal delivery system that targets the nerves in the skin. It is locally-acting and non-narcotic, and unlikely to cause drowsiness or interact with other drugs. Qutenza can be used alone or with other pain medications.  

Each year, about one million Americans develop shingles, a painful viral infection caused by a reactivation of the same virus that causes chickenpox. It is estimated that up to one in five people with shingles will experience prolonged pain after shingles, known as PHN. The pain can persist long after the shingles rash clears up and can disrupt sleep, mood, work and the activities of daily living.

"PHN can be an excruciatingly painful condition that can greatly affect many aspects of a person's daily living," said Lynn Webster, M.D., medical director, Lifetree Clinical Research, Salt Lake City, Utah. "Despite the current availability of a variety of pain medications, undesirable side effects, such as drowsiness and interactions with other drugs, often limit their use. Because of these limitations, there is still a need for new treatment options for PHN, and, more importantly, many patients are still suffering. Qutenza may provide a unique treatment option for patients. It is targeted directly to the site of the pain and may be used alone or in combination with existing therapies."

"I have suffered from post-shingles pain for more than four years," said Brad Smith, a 68-year-old husband, father of four, and PHN patient who participated in the Qutenza clinical trials. "I tolerated tremendous pain every day. Qutenza gave me relief, and I was grateful for the treatment."

The active ingredient in Qutenza is a synthetic form of capsaicin, a naturally occurring compound found in chili peppers that gives them their heat sensation. Qutenza is applied directly to the painful site by a physician or health care professional under the close supervision of a physician.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
NGSX $0.01 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs